Process and product development in the manufacturing of molecular therapeutics.
In the development of molecular therapies, a great deal of attention has focused on tissue targets, gene delivery vectors, and expression cassettes. In order to become an approved therapy, however, a molecular therapeutic has to pass down the same product registration pathway as any other biological product. Moving from research into industrial production requires careful attention to regulatory, manufacturing and quality concerns. Early work on developing and characterizing robust and scaleable manufacturing processes will ultimately be rewarded by ease of implementation as the product is successful in clinical trials. Regulatory agencies require solid process and product characterization studies to demonstrate control and understanding of the molecular therapeutic. As the gene therapy industry matures, standards will continue to rise, creating an industry that is capable of producing safe, high-quality and effective therapies for many of the world's most difficult disease targets.
Atkinson
E M
EM
Targeted Genetics Corporation, Seattle, WA 98101 USA. atkinson@targen.com
Christensen
J R
JR
D000818:Animals; D001315:Australia; D002986:Clinical Trials as Topic / Q000592:standards; D003001:Cloning, Molecular / Q000379:methods; D003257:Consumer Product Safety; D004274:DNA, Recombinant / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D004345:Drug Industry / Q000379:methods; D005062:European Union; D015316:Genetic Therapy / Q000592:standards; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics / Q000302:isolation & purification / Q000592:standards; D006801:Humans; D020407:Internet; D007564:Japan; D051379:Mice; D020416:Outsourced Services; D015203:Reproducibility of Results; D014481:United States; D014486:United States Food and Drug Administration
D004274:DNA, Recombinant